Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023)

BackgroundIn Europe, the combination of cabotegravir (CAB) with rilpivirine (RPV) has been approved as a dual injection long-acting (LA) therapy for the treatment of human immunodeficiency virus type 1 (HIV-1) infections in adults since December 2020. Studies have shown that between 36 and 61% of pe...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Schmidt (Author), Christian Kollan (Author), Matthias Stoll (Author)
Format: Book
Published: Frontiers Media S.A., 2024-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available